keyword
MENU ▼
Read by QxMD icon Read
search

metformin and weight loss

keyword
https://www.readbyqxmd.com/read/29760945/liraglutide-and-dulaglutide-therapy-in-addition-to-sglt-2-inhibitor-and-metformin-treatment-in-indian-type-2-diabetics-a-real-world-retrospective-observational-study
#1
S Ghosal, B Sinha
Background: Therapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon like Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation of SGLT2i and GLP-1RA in the DURATION 8 trial an improvement in HbA1c was noted but the beneficial effect was not equal to the sum of its parts. In view of this we proceeded to test the hypothesis that sequential addition of GLP-1RA therapy to metformin and SGLT-2i may be more beneficial...
2018: Clinical Diabetes and Endocrinology
https://www.readbyqxmd.com/read/29740791/nonalcoholic-fatty-liver-disease-in-children-not-a-small-matter
#2
REVIEW
Praveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Naim Alkhouri
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased substantially in the past two decades and NAFLD has now become the most common cause of chronic liver disease in children and adolescents. NAFLD is a broad clinicopathologic spectrum ranging from simple steatosis to varying degrees of necroinflammation called nonalcoholic steatohepatitis (NASH), leading to fibrosis and subsequently to cirrhosis. Despite the increasing prevalence and progressive nature of NAFLD even among children, therapy for NAFLD in both adults and children are limited...
May 9, 2018: Paediatric Drugs
https://www.readbyqxmd.com/read/29731652/adjunctive-therapy-for-glucose-control-in-patients-with-type-1-diabetes
#3
REVIEW
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise
Type 1 diabetes mellitus (T1DM) is characterized by relative or absolute insulin deficiency. Despite treatment with insulin therapy, glycemic goals are not always met, and insulin therapy is sometimes limited by adverse effects, including hypoglycemia and weight gain. Several adjunctive therapies have been evaluated in combination with insulin in patients with T1DM to improve glycemic control while minimizing adverse effects. Pramlintide, an amylin analog, can improve glycemic control, primarily through lowering postprandial blood glucose levels...
2018: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29716897/prospective-randomized-biomarker-study-of-metformin-and-lifestyle-intervention-for-prevention-in-obese-women-at-increased-risk-for-endometrial-cancer
#4
Melinda S Yates, Adriana M Coletta, Qian Zhang, Rosemarie E Schmandt, Meena Medepalli, Denise R Nebgen, Beth Soletsky, Andrea Milbourne, Erma Levy, Bryan M Fellman, Diana L Urbauer, Ying Yuan, Russell R Broaddus, Karen Basen-Engquist, Karen Lu
Obesity increases risk of endometrial cancer through dysregulation of estrogen and insulin signaling. The primary aim of this study was to evaluate the impact of metformin or lifestyle intervention on endometrial proliferation in postmenopausal obese women. Secondary aims included evaluating obesity-related biomarkers and adverse events experienced. Obese, postmenopausal women with pre-diabetes were randomized into four groups for a 16-week intervention using a 2 (metformin 1700 mg/day vs placebo) x 2 (lifestyle intervention vs no lifestyle intervention) factorial design...
May 1, 2018: Cancer Prevention Research
https://www.readbyqxmd.com/read/29693359/a-retrospective-real-world-study-of-dapagliflozin-versus-other-oral-antidiabetic-drugs-added-to-metformin-in-patients-with-type-2-diabetes
#5
Huan Huang, Kelly F Bell, Ray Gani, Cathy W Tugwell, James M Eudicone, Michelle R Krukas-Hampel
OBJECTIVES: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. METHODS: Electronic medical record (EMR) data were used to compare clinical outcomes among patients with type 2 diabetes (T2D) treated with dapagliflozin and metformin with or without other oral antidiabetic drugs (D + M ± OAD), versus metformin with at least 1 other OAD (M + OAD)...
April 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29673333/protocol-for-the-chord-project-community-health-outreach-to-reduce-diabetes-a-cluster-randomized-community-health-worker-trial-to-prevent-diabetes
#6
Nadia Islam, Thomas Gepts, Isaac Lief, Radhika Gore, Natalie Levy, Michael Tanner, Yixin Fang, Scott E Sherman, Mark D Schwartz
BACKGROUND: Type 2 diabetes mellitus (DM) affects 9.4% of US adults and children, while another 33.9% of Americans are at risk of DM. Health care institutions face many barriers to systematically delivering the preventive care needed to decrease DM incidence. Community health workers (CHWs) may, as frontline public health workers bridging clinic and community, help overcome these challenges. This paper presents the protocol for a pragmatic, cluster-randomized trial integrating CHWs into two primary care clinics to support DM prevention for at-risk patients...
April 19, 2018: BMC Public Health
https://www.readbyqxmd.com/read/29670753/association-of-changes-in-mental-health-with-weight-loss-during-intensive-lifestyle-intervention-does-the-timing-matter
#7
N Alhalel, S M Schueller, M J O'Brien
Objective: This study examined changes in mental health symptoms and weight during weight loss treatment. It was hypothesized that worsening mental health would negatively impact weight loss. Methods: Data were analyzed from a trial of 92 Hispanic women with overweight/obesity and prediabetes, who were randomized to receive intensive lifestyle intervention (ILI), metformin 1,700 mg daily, or standard care. Depression, anxiety and perceived stress were assessed at 0, 6 and 12 months...
April 2018: Obesity Science & Practice
https://www.readbyqxmd.com/read/29666753/effect-of-metformin-monotherapy-on-serum-lipid-profile-in-statin-na%C3%A3-ve-individuals-with-newly-diagnosed-type-2-diabetes-mellitus-a-cohort-study
#8
Szu Han Lin, Po Chung Cheng, Shih Te Tu, Shang Ren Hsu, Yun Chung Cheng, Yu Hsiu Liu
Background: Cardiovascular disease is a major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM). Studies have consistently identified dyslipidemia as an important risk factor for the development of macrovascular disease. The landmark United Kingdom Prospective Diabetes Study has shown that metformin therapy reduces cardiovascular events in overweight people with T2DM. This study investigates the effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed T2DM, and whether the effect, if any, is dosage-related...
2018: PeerJ
https://www.readbyqxmd.com/read/29662261/prediabetes-in-colombia-expert-consensus
#9
REVIEW
Patricio López-Jaramillo, Carlos Calderón, Jorge Castillo, Iván Darío Escobar, Enrique Melgarejo, Gustavo Adolfo Parra
The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our expert group recommends that educational programs emphasize a global approach to risk which includes a recognition of the importance of prediabetes and its evaluation along with and other risk factors such as a family history of DM2, overweight and obesity, dislipidemia and hypertension...
December 30, 2017: Colombia Médica: CM
https://www.readbyqxmd.com/read/29658344/effect-of-12-month-treatment-with-metformin-and-or-oral-contraceptives-on-health-related-quality-of-life-in-polycystic-ovary-syndrome
#10
Magda Lambaa Altinok, Pernille Ravn, Marianne Andersen, Dorte Glintborg
Health-related quality of life (HRQoL) is impaired in polycystic ovary syndrome (PCOS), but the effect of treatment with metformin (M) and/or oral contraceptives (OCP) is undetermined. To assess changes in HRQoL during 12-month randomized treatment with M, OCP or M + OCP in PCOS. Ninety women with PCOS were randomized to treatment with M, OCP or M + OCP. HRQoL was evaluated by a PCOS-specific visual analog scale (PCOS-VAS) regarding 1: Facial hair, 2: Body hair, 3: Acne, 4: Irregular menses, 5: Weight and 6: PCOS in general, and Short Form 36 (SF-36)...
April 16, 2018: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29609858/undetectable-high-density-lipoprotein-cholesterol-in-acute-malaria
#11
Ana Rakovac Tisdall, Vivion Edward Francis Crowley, Martin Andrew Crook
We report the case of a 39-year-old West African man in whom high-density lipoprotein cholesterol (HDL-C) was identified as undetectable at <0.08 mmol/L. Total cholesterol in the same sample was 2.85 mmol/L; triglycerides were only mildly elevated at 2.32 mmol/L. He was admitted with a 2-week history of polydipsia, polyuria, weight loss and hyperpyrexia. Dual malarial infection with Plasmodium ovale and falciparum was identified and attributed to a recent trip to Nigeria without chemoprophylaxis. Also, he was diagnosed with diabetes mellitus with random hyperglycemia of 39 mmol/L but no ketonemia...
March 9, 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29573139/effects-of-exenatide-once-weekly-plus-dapagliflozin-exenatide-once-weekly-or-dapagliflozin-added-to-metformin-monotherapy-in-subgroups-of-patients-with-type-2-diabetes-in-the-duration-8-randomized-controlled-trial
#12
Juan P Frías, Elise Hardy, Azazuddin Ahmed, Peter Öhman, Serge Jabbour, Hui Wang, Cristian Guja
This analysis assessed whether responses with exenatide once weekly (QW) plus dapagliflozin (n=231), exenatide QW (n=230), or dapagliflozin (n=233) differed in key patient subpopulations of the DURATION-8 trial. Potential treatment-by-subgroup interactions for changes in glycated haemoglobin (HbA1c) and body weight after 28 weeks were evaluated among subgroups determined by baseline HbA1c, age, sex, body mass index, type 2 diabetes duration, race, ethnicity, and estimated glomerular filtration rate (eGFR). Exenatide QW plus dapagliflozin reduced HbA1c and body weight across all subgroups; least-squares mean (LSM) reductions ranged from -8...
March 23, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29500217/comet-a-protocol-for-a-randomised-controlled-trial-of-co-commencement-of-metformin-as-an-adjunctive-treatment-to-attenuate-weight-gain-and-metabolic-syndrome-in-patients-with-schizophrenia-newly-commenced-on-clozapine
#13
Dan Siskind, Nadia Friend, Anthony Russell, John J McGrath, Carmen Lim, Sue Patterson, Dylan Flaws, Terry Stedman, Vikas Moudgil, Savio Sardinha, Shuichi Suetani, Steve Kisely, Karl Winckel, Andrea Baker
INTRODUCTION: Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation. METHODS AND ANALYSIS: A 24-week double-blind placebo-controlled trial of concomitant prescription of metformin at clozapine commencement...
March 2, 2018: BMJ Open
https://www.readbyqxmd.com/read/29483185/efficacy-and-safety-of-ideglira-versus-basal-bolus-insulin-therapy-in-patients-with-type-2-diabetes-uncontrolled-on-metformin-and-basal-insulin-the-dual-vii-randomized-clinical-trial
#14
Liana K Billings, Ankur Doshi, Didier Gouet, Alejandra Oviedo, Helena W Rodbard, Nikolaos Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jodar
OBJECTIVE: In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. RESEARCH DESIGN AND METHODS: A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day...
May 2018: Diabetes Care
https://www.readbyqxmd.com/read/29482528/comparison-of-glycemic-control-and-%C3%AE-cell-function-in-new-onset-t2dm-patients-with-pcos-of-metformin-and-saxagliptin-monotherapy-or-combination-treatment
#15
Tao Tao, Peihong Wu, Yuying Wang, Wei Liu
BACKGROUND: Impaired insulin activity in women with polycystic ovary syndrome might differ from that seen in type 2 diabetes mellitus without polycystic ovary syndrome. This study was designed to compare the effects of treatment with metformin, saxagliptin, and their combination in newly diagnosed women with type 2 diabetes mellitus and polycystic ovary syndrome in China. METHODS: A total of 75 newly diagnosed patients from Shanghai, China with type 2 diabetes mellitus and polycystic ovary syndrome were included in this randomized, parallel, open-label study...
February 27, 2018: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29480037/pharmacological-management-of-diabetes-in-severe-mental-illness-a-comprehensive-clinical-review-of-efficacy-safety-and-tolerability
#16
REVIEW
John Lally, Aonghus O' Loughlin, Brendon Stubbs, Allys Guerandel, Donal O'Shea, Fiona Gaughran
The increased prevalence of Type 2 diabetes mellitus (T2DM) in severe mental illness (SMI) contributes to increased cardiovascular morbidity and reduced life expectancy for people with SMI. Areas covered: In the present clinical review, we summarize the efficacy, safety and tolerability of selected diabetic pharmacotherapy options in SMI and discuss the quality and strength of evidence. Expert commentary: General principles for treating T2DM in SMI involve identifying treatments which promote weight loss and which have low or no risk of hypoglycemia...
April 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29477373/comparing-sglt-2-inhibitors-to-dpp-4-inhibitors-as-an-add-on-therapy-to-metformin-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#17
REVIEW
B M Mishriky, R J Tanenberg, K A Sewell, D M Cummings
AIMS: Our aim was to compare Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) to Dipeptidyl peptidase-4 inhibitors (DPP-4i) as add-on therapy to metformin. METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We pooled trials reporting outcomes between 12 and 26 weeks together while trials reporting results ≥52 weeks were pooled together. The primary outcomes were the change in haemoglobin A1c (A1c) at ≤26 and ≥52 weeks...
March 2018: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29477037/evaluation-of-the-neonatal-streptozotocin-model-of-diabetes-in-rats-evidence-for-a-model-of-neuropathic-pain
#18
Paulino Barragán-Iglesias, Víctor Hugo Oidor-Chan, Emanuel Loeza-Alcocer, Jorge Baruch Pineda-Farias, Isabel Velazquez-Lagunas, Ana Belen Salinas-Abarca, Enrique Hong, Alicia Sánchez-Mendoza, Rodolfo Delgado-Lezama, Theodore J Price, Vinicio Granados-Soto
BACKGROUND: The purpose of this study was to evaluate the participation of satellite glial cells (SGC), microglia and astrocytes in a model of streptozotocin-induced diabetes initiated in neonatal rats (nSTZ) and to determine the pharmacological profile for pain relief. METHODS: nSTZ was used to induce experimental diabetes. Von Frey filaments were used to assess tactile allodynia. Drugs were given by systemic administration. Western blotting and immunohistochemistry were used to determine protein expression and cellular localization...
April 2018: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29452178/effects-of-canagliflozin-versus-glimepiride-on-adipokines-and-inflammatory-biomarkers-in-type-2-diabetes
#19
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies
OBJECTIVE: Type 2 diabetes and obesity are pro-inflammatory states associated with increased risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated superiority in lowering HbA1c versus glimepiride with less hypoglycemia and greater weight reduction via loss of fat mass in a 52-week trial of type 2 diabetes patients. This post hoc, exploratory analysis assessed the effects of canagliflozin versus glimepiride on select adipokines, inflammatory biomarkers, and chemokines...
February 13, 2018: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29415360/metformin-induced-encephalopathy-the-role-of-thiamine
#20
Caoimhe McGarvey, Catherine Franconi, David Prentice, Michael Bynevelt
A case of metformin encephalopathy is presented in a patient on haemodialysis for end-stage diabetic renal failure. The patient presented with frequent falls and clinical signs of Parkinsonism, on a background of recent anorexia and significant weight loss. Magnetic resonance imaging showed bilateral, symmetrical abnormalities centred on the lentiform nuclei. Metformin was withheld and signs and symptoms quickly resolved. We hypothesise that metformin may cause thiamine deficiency in patients with end-stage renal failure resulting in a specific metabolic encephalopathy...
February 2018: Internal Medicine Journal
keyword
keyword
99421
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"